https://www.selleckchem.com/products/kp-457.html Time to progression (TTP) is the length of time from the date of diagnosis or the start of treatment to disease progression. In the analysis of TTP, standard survival analysis, where death events are censored, may be problematic and competing risks analysis should be used instead. We investigated statistical methods used in the analysis of TTP. We performed a literature search in six oncology journals for original articles published between 2016 and 2020. We only included articles where TTP was analyzed. After excluding articles in which the events of interest included death or in which the definition of TTP was not specified, we sought to learn whether TTP was analyzed by standard survival analysis or competing risks analysis. Of the 143 articles in which TTP was evaluated, 65 that defined the event of interest as only progression were included in the study. Of the 65 articles analyzed, 43 (66%) were on solid tumors and 22 (34%) were on hematologic tumors. In 59 (91%) of the 65 articles, standard survival analysis was performed. The event of interest was mostly defined as progression without inclusion of any death event. In most recent articles on oncology, TTP seems to be analyzed by standard survival analysis. There is much room for improvement in the statistical methods in the analysis of TTP in oncology research. The event of interest was mostly defined as progression without inclusion of any death event. In most recent articles on oncology, TTP seems to be analyzed by standard survival analysis. There is much room for improvement in the statistical methods in the analysis of TTP in oncology research. This study aimed to evaluate the involvement of the orexin system in predictable chronic mild stress (PCMS) and the effects of suvorexant, a dual orexin receptor antagonist, on nociceptive behavior in PCMS. Male C57BL/6J mice were separated into various PCMS groups a control group with sawdust on the floor of the re